Stripe's $53B PayPal Offer, Avere's Reverse Merger, and Three More Deals

The largest headline is still only an approach: Stripe and Advent International have offered more than $53 billion for PayPal, but PayPal has not responded and Reuters says there is no certainty the bid becomes a transaction. Alongside it, the week brought a signed reverse merger for Avere, a global oncology license for AstraZeneca, a completed royalty-platform acquisition by Ligand, and a reported Tencent-led effort to buy Manus back from Meta.

Stripe and Advent offered $60.50 per PayPal share, valuing the payments company at more than $53 billion. The approach was submitted earlier in July and is backed by about $50 billion in committed bank financing, but PayPal, Stripe, and Advent declined to comment; the sources said PayPal had not responded. Stripe and Advent would jointly own the company in equal stakes rather than split it up. 1

PayPal was founded in the late 1990s and remains a large digital-payments platform spanning checkout, Venmo, and payments and crypto. Reuters reported $8.35 billion of first-quarter revenue and about $464 billion of payment volume, while also describing slowing growth and heavier competition from Apple Pay and Google Pay. The strategic case is an inference from the reported structure and sector context: the buyers appear to be seeking payments scale and exposure to faster-growing business-to-business and cross-border flows, but neither buyer has stated a public rationale for this approach. 1

Tencent is in talks to become Manus' largest shareholder. Reuters reported that Tencent and Manus' original investors, including ZhenFund and HSG, are planning to buy the company back from Meta for no less than $2 billion. This is a reported plan, not a definitive agreement. Beijing had ordered Meta to unwind its earlier $2 billion acquisition, and the reported buyback would restore ownership to Tencent and earlier backers if the talks produce a deal. 2

Manus builds AI agents that can carry out tasks with minimal human input. It moved its operations from China to Singapore last year and had been positioned as a general-purpose agent platform. The strategic rationale is therefore partly regulatory: preserve control of an agentic-AI asset after a cross-border transaction was challenged, while keeping Tencent close to the technology. That reading is an inference from the ownership talks and the Beijing order, not a stated Tencent plan. 2

Avere Therapeutics and NextCure announced a definitive all-stock merger on July 14. The combined company is expected to operate as Avere and trade on Nasdaq under AVRX after closing in the second half of 2026. A concurrent $320 million private placement, including $251 million of convertible notes, is intended to fund AVR-001 through a psoriasis Phase 2b readout, the start of a Phase 3 trial, and the start of a Phase 2b ulcerative-colitis trial. 6

AVR-001 is an oral peptide IL-23 receptor antagonist licensed from Hansoh on an ex-Greater China basis. Hansoh is due $120 million upfront and up to $2.18 billion in development and sales milestones, plus sales royalties. The drug is engineered for an approximately 100-hour half-life to support once-weekly dosing. Avere's strategic move is explicit: combine the program with NextCure's public-market infrastructure and use the financing to reach multiple clinical inflection points. 36

AstraZeneca signed an exclusive global license with Dizal Pharmaceutical for Zegfrovy, also known as sunvozertinib. The oral, irreversible EGFR inhibitor is being developed for lung cancer, including EGFR exon 20 insertion mutations. AstraZeneca will pay $600 million upfront, up to $900 million on development, regulatory, and sales milestones, and tiered royalties on global sales; the agreement is expected to close in the second half of 2026. 4

AstraZeneca said the deal adds a differentiated oral targeted option to its EGFR-mutated lung-cancer portfolio and uses its global oncology reach to extend a China-originated asset to patients worldwide. This is a license rather than a company acquisition, so the headline $1.5 billion is the maximum stated upfront-plus-milestone amount and excludes the separate royalty stream. 4

Ligand completed its acquisition of XOMA Royalty on July 14 for $39 per common share and an approximately $739 million equity value. XOMA holders also received one non-transferable contingent value right tied to a portion of 75% of net proceeds that may come from certain pending litigation. The agreement was announced on April 27, so this week's event is the closing, not a newly signed transaction. 57

XOMA Royalty buys the future economics attached to pre-commercial and commercial therapeutic candidates, giving biotech sellers non-dilutive, non-recourse funding. Ligand said the acquisition adds seven commercial products, 14 late-stage development programs, and more than 100 other assets, taking its combined portfolio above 200 royalty assets. The buyer's stated rationale is portfolio breadth and durable royalty income; it also expects the transaction to add about $0.50 to 2026 adjusted EPS and $1.50 to 2027 adjusted EPS. 57

The week spans an unaccepted offer, reported talks, a reverse merger with a financing, a license with milestones, and a completed acquisition with contingent value rights. The headline amounts are therefore not directly comparable: PayPal's figure is an offer value, Avere's $320 million is financing rather than merger consideration, AstraZeneca's $1.5 billion is a maximum upfront-plus-milestone package, and Ligand's $739 million is equity value before the CVR.

PayPal gives a potential buyer a scaled payments network; AstraZeneca supplies global development and commercialization capacity to a China-originated lung-cancer asset; and Ligand adds a large stream of rights to commercial and clinical-stage medicines. Avere's transaction uses public-market access and fresh capital to move one oral IL-23 program through several trials. Across these structures, the asset is only half the purchase case. The other half is the buyer's ability to fund, develop, or distribute it.

Dizal is licensing Zegfrovy's global rights to AstraZeneca, while Hansoh is financing Avere and licensing AVR-001 rights outside Greater China. Manus is the more political version of the same ownership question: a Chinese investor group is reported to be trying to regain control of an AI company after Beijing challenged Meta's ownership. The common thread is not a single valuation trend, but the way cross-border ownership and commercialization rights are being separated.

No qualifying SaaS acquisition with a disclosed transaction value was added this week. Reuters reported that CCC Intelligent Solutions was exploring a sale, but it did not report a transaction price; the company is therefore outside the five-deal count. 8